The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 53.00
Ask: 56.00
Change: 0.00 (0.00%)
Spread: 3.00 (5.66%)
Open: 54.50
High: 54.50
Low: 54.50
Prev. Close: 54.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

11 Feb 2022 07:00

RNS Number : 4135B
MyCelx Technologies Corporation
11 February 2022
 

11 February 2022

 

MYCELX TECHNOLOGIES CORPORATION (AIM: MYX)

 

Trading Update

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company, is pleased to announce a trading update on the Company's operations.

 

Highlights

 

· Anticipated unaudited 2021 revenue of ca.$8.5 million (2020: $7.1 million)

 

· As at 31 December 2021, the Company had cash and cash equivalents, including restricted cash, of $3.2 million (2021 H1: $5.5 million), and the Company continues to manage its working capital and support growth

· Operations continue to perform in line with expectations, with minimal to no impact of Covid-19 in MYCELX's day-to-day business functions

 

· In 2022 the Company is targeting a similar level of year-on-year revenue growth but this remains subject to the timing of anticipated contract wins and renewals

 

Commenting on these results, Connie Mixon, CEO, said:

 

"We are very pleased with how the Company performed in the second half of 2021 and based on the start of the year, we are targeting to deliver year-on-year growth to our stakeholders in 2022. Oil prices are at their highest levels since 2014, which we anticipate will lead to greater levels of production activity across the regions in which we operate and will likely lead to heightened demand for our environmental solutions in these areas.

 

We were pleased to report a successful outcome at our PFAS trial in the United States in December, as we believe the PFAS remediation market has the potential to generate substantial cash flows for the business for the foreseeable future.

 

Finally, we continue to successfully navigate the Covid-19 pandemic, with the Company now experiencing little to no impact on its day-to-day operations. However, we continue to take all precautions necessary in order to safeguard the welfare of our workforce."

 

 

For further information, please contact: 

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

Tel: +1 888 306 6843

 

Canaccord Genuity Limited (Nomad and Sole Broker)

Henry Fitzgerald-O'Connor

Gordon Hamilton

 

 

Tel: +44 20 7523 8150

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

 

Tel: +44 20 8434 2754

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFDSMFEESEFE
Date   Source Headline
4th Mar 20167:00 amRNSTrading Update
11th Jan 20165:30 pmRNSHolding(s) in Company
29th Dec 20152:23 pmRNSHolding(s) in Company
18th Dec 201510:13 amRNSHolding(s) in Company
15th Dec 20155:25 pmRNSHolding(s) in Company
15th Dec 20155:24 pmRNSHolding(s) in Company
11th Dec 20157:00 amRNSTrading Update
3rd Dec 201511:33 amRNSBlocklisting Interim Review
1st Oct 20157:00 amRNSProgress Update on Trials
10th Sep 20157:00 amRNSHalf Yearly Report
28th Aug 20157:00 amRNSRestricted Common Shares to be Traded in CREST
20th Aug 20157:00 amRNSDirector Resignation
17th Aug 20157:00 amRNSProgress Report on Trials and Cost Reduction
29th Jul 20152:01 pmRNSHolding(s) in Company
22nd Jul 20157:00 amRNSTrading Statement
1st Jul 20157:00 amRNSChange of Adviser
5th Jun 20157:00 amRNSDirector/PDMR Shareholding
28th May 20159:48 amRNSBlocklisting Interim Review
21st May 20153:01 pmRNSDirector/PDMR Shareholding
19th May 20154:01 pmRNSResult of Annual Meeting
19th May 20157:00 amRNSAnnual Meeting Statement
17th Apr 20157:00 amRNSMailing of 2014 Annual Report & Notice of AGM
20th Mar 20157:00 amRNS2014 Preliminary Results
15th Jan 20155:39 pmRNSTrading Update
5th Jan 20157:00 amRNSClose of US Placing
2nd Jan 201512:00 pmRNSHolding(s) in Company
22nd Dec 201412:54 pmRNSHolding(s) in Company
10th Dec 20147:00 amRNSEquity Placing
2nd Dec 20147:00 amRNSEquity Placing
27th Nov 20143:58 pmRNSBlocklisting Interim Review
19th Nov 20147:00 amRNSTrading Statement
12th Sep 20147:00 amRNSHalf Year Results Statement
26th Aug 20147:00 amRNSMiddle East Contract Win
7th Jul 20147:00 amRNSHalf Year Trading Update & Contract Wins
13th May 20143:31 pmRNSResult of Annual Meeting
29th Apr 20144:44 pmRNSBlocklisting Interim Review
22nd Apr 201410:02 amRNSAnnual Report & Accounts Posted
20th Mar 20147:00 amRNS2013 Preliminary Results
30th Jan 20147:00 amRNSYear End Trading Update & Contract Wins
10th Dec 20133:29 pmRNSTotal Voting Rights
4th Dec 20133:24 pmRNSHolding(s) in Company
26th Nov 20137:00 amRNSFast-to-market lease programme yields new leasings
30th Oct 20133:21 pmRNSDirector/PDMR Shareholding
29th Oct 20131:56 pmRNSBlocklisting Interim Review
16th Oct 20133:12 pmRNSDirector Shareholding / Warrant Exercise
3rd Oct 20137:00 amRNSInvestor Presentation
12th Sep 20137:00 amRNSHalf Year Results Statement
19th Aug 20139:06 amRNSNotice of Results
7th Aug 20139:29 amRNSBalance of respective lines of stock
10th Jun 20135:16 pmRNSChange of Main Office Address

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.